muscimol has been researched along with Parkinson Disease, Secondary in 7 studies
Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.
muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, D | 1 |
| Karain, B | 1 |
| Brantley, E | 1 |
| Shi, WX | 1 |
| Wichmann, T | 3 |
| Bergman, H | 1 |
| DeLong, MR | 3 |
| Kurokawa, M | 1 |
| Koga, K | 1 |
| Kase, H | 1 |
| Nakamura, J | 1 |
| Kuwana, Y | 1 |
| Basso, MA | 2 |
| Powers, AS | 1 |
| Evinger, C | 2 |
| Kliem, MA | 1 |
| Baron, MS | 1 |
| Ma, D | 1 |
7 other studies available for muscimol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Electrophy | 2011 |
The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Bicuculline; Brain Mapping | 1994 |
Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo.
Topics: Acetylcholine; Adenosine; Animals; Corpus Striatum; Drug Combinations; GABA Antagonists; Male; Musci | 1996 |
An explanation for reflex blink hyperexcitability in Parkinson's disease. I. Superior colliculus.
Topics: Animals; Blinking; Electric Stimulation; GABA Agonists; Microinjections; Muscimol; Oxidopamine; Park | 1996 |
An explanation for reflex blink hyperexcitability in Parkinson's disease. II. Nucleus raphe magnus.
Topics: Animals; Blinking; Electric Stimulation; GABA Agonists; Male; Microinjections; Muscimol; Neural Path | 1996 |
Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carrier Proteins; Dopamine | 2001 |
Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2002 |